Urticaria and angioedema as possible reactions of omalizumab

Özbağçıvan, Özlem; Akarsu, Sevgi; İlknur, Turna; Fetil, Emel

doi:10.1590/abd1806-4841.20187074

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immediate treatment effects included a patient that developed a widespread urticarial reaction to their seventh infusion of adalimumab, 22 including lip swelling, and a patient who experienced new mild swelling of the face including the lips after omalizumab injections that resolved with tranexamic acid treatment 23 . Intermediate and delayed effects also occurred, including tongue swelling after repeated adalimumab administration and severe angioedema of the lips and tongue 12 h after the fifth injection of omalizumab 24,25 . Other later onset effects included a patient developing facial and lower extremity edema on adalimumab that subsequently resolved when the patient was switched to certolizumab, and a patient who initially developed gingival dysesthesia during treatment with efalizumab that progressed to tongue and facial swelling 26,27 .…”

Section: Resultsmentioning

confidence: 99%

“…23 Intermediate and delayed effects also occurred, including tongue swelling after repeated adalimumab administration and severe angioedema of the lips and tongue 12 h after the fifth injection of omalizumab. 24,25 Other later onset effects included a patient developing facial and lower extremity edema on adalimumab that subsequently resolved when the patient was switched to certolizumab, and a patient who initially developed gingival dysesthesia during treatment with efalizumab that progressed to tongue and facial swelling. 26,27 Edema of the buccal, lingual and periorbital mucosa have also been reported.…”

Section: Angioedemamentioning

confidence: 99%

See 1 more Smart Citation

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review

France

Yogarajah

Gueiros

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background Biologic agents are rapidly emerging as an effective therapy to treat autoimmune and other chronic diseases. The use of these agents is poorly characterized, resulting in a lack of guidance for dental practitioners. Case reports of oral adverse events have begun to emerge. However, their scope and frequency have not been summarized and analysed to date. The objective of this review was to characterize the literature on oral adverse effects associated with biological therapy when used for autoimmune and inflammatory disorders. Methods This review was developed in accordance with scoping review recommendations. Search strategies were developed and employed for six databases. Studies were selected using a systematic search process but with broad inclusion of study types given the paucity of information available. Reports of oral adverse events were analysed descriptively according to agent, mechanism of action, underlying disease, and oral adverse effect observed. Results Our search returned 2080 articles and 51 met our inclusion criteria, of which most were case reports. The most frequent adverse effects included angioedema, oral lichenoid lesions, osteonecrosis of the jaw, and oral infections. There were also cases of oral malignancies associated with use of biologic agents. Less common effects such as pigmentation were also described. Conclusions Oral adverse events have been reported in patients on biologic therapy, albeit in small numbers to date. This limits the generalizability of these results, which should not be used to generate a clinical guideline as they are based primarily on case reports. However, this study presents the first review characterizing the adverse effects observed. Large multi‐center studies will be necessary to further define the oral and dental complications caused by biologic agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Angioedemamentioning

confidence: 99%

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review

France

Yogarajah

Gueiros

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Omalizumab

2018

Reactions Weekly

View full text Add to dashboard Cite

Omalizumab maintains a longer remission period than predicted: An observational study

TÜRSEN

Aktaş

2021

Mersin Üniversitesi Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

Amaç: Omalizumab, antihistaminlere dirençli kronik ürtiker tedavisinde kullanılan monoklonal anti IgE antikorudur. Her dört haftada bir uygulama önerilmektedir. Yöntem: Kronik ürtiker tanısıyla izlenen 15 hastanın subkutan omalizumab tedavisine yanıtı yaş, cinsiyet, ürtiker süresi ve şiddetinin omalizumab ile elde edilen remisyon süresine etkisi incelendi. Bulgular: Yaş ortalaması 43.9±7.8 olan 8 kadın 7 erkek hastada ortalama 6.26±2.7 hafta remisyon sağlandı. Yaş, cinsiyet, ürtiker süre ve şiddeti remisyon süresini etkilemezken, ürtikerine astım eşlik eden hastalarda remisyon süresinin kısa olduğu gözlendi. Sonuç: Omalizumab dört hafta olarak belirlenen etki süresinden daha uzun remisyon sağlamaktadır.

show abstract

Urticaria and angioedema as possible reactions of omalizumab

Cited by 3 publications

References 4 publications

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review

Omalizumab

Omalizumab maintains a longer remission period than predicted: An observational study

Contact Info

Product

Resources

About